Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to investigate the efficacy and safety of surgery
combined with rAd-p53 gene therapy in treatment of advanced Non-small-cell lung carcinoma
(NSCLC). The study efficacy endpoints include overall survival, progress-free survival,
quality of life, and local recurrent rate. The safety endpoint is complications and adverse
effects.
The study hypothesis: rAd-p53 gene therapy can prolong the overall survival and reduce the
local recurrent rate.